The Effect of Inflammatory Markers on the Survival of Advanced Gastric Cancer Patients Who Underwent Anti-Programmed Death 1 Therapy

Ziting Qu†, Qianling Wang†, Hui Wang†, Yang Jiao, Min Li, Wei Wei, Yu Lei, Zhiyan Zhao, Tengteng Zhang, Yiyin Zhang‡ and Kangsheng Gu‡

Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China

Purpose: This clinical study sought to determine whether the levels of inflammatory markers predicted the survival of advanced gastric cancer (AGC) patients who underwent anti-programmed death 1 (PD-1) therapy.

Methods: Using AGC patient plasma samples and baseline characteristics, we investigated the specific value of inflammatory markers in AGC from a clinical perspective in immunotherapy.

Results: One hundred and six patients with AGC who underwent anti-PD-1 therapy were enrolled in this study between 20 July 2019 and 16 March 2021. A significant decrease in NLR, dNLR, and SII was noticed among the PR (P=0.023; P=0.036; P=0.001), SD (P=0.048; P=0.022; P=0.023), ORR (P=0.021; P=0.032; P=0.001), and DCR (P=0.003; P=0.001; P<0.001) groups after anti-PD-1 therapy. Additionally, a significant decline of PLR was also observed in PR (P=0.010), ORR (P=0.007), and DCR (P=0.005) after anti-PD-1 therapy. Only MLR levels increased significantly at the time of anti-PD-1 immunotherapy the failure compared to baseline (P=0.039). And statistically significant elevations in NLR (P=0.001), MLR (P=0.020), dNLR (P=0.002), and SII (P=0.019) were found in failure of anti-PD-1 treatment compared to optimal efficacy in AGC patients. In first-line treatment, the number of metastatic sites (P=0.001) was an independent prognostic factor for PFS, and peritoneal metastases (P=0.004) and platelet-to-lymphocyte ratio (PLR) level (P=0.014) were independent prognostic predictors of OS according to Cox regression analysis. In second-line or posterior treatment, the number of metastatic sites (P=0.007), ECOG (P=0.011), and PLR level (P=0.033) were independent prognostic factors for PFS in AGC patients, and the number of metastatic sites (P=0.003), differentiation (P=0.030), and NLR level (P<0.001) were independent prognostic factors for OS according to Cox regression analysis.

Conclusions: NLR, PLR, MLR, dNLR, and SII can reflect the short-term efficacy of immunotherapy in patients who underwent anti-PD-1 therapy with AGC. PLR is an independent prognostic factor for OS in AGC patients receiving first-line immunotherapy and PFS in those receiving second-line or posterior immunotherapy. And NLR was an
INTRODUCTION

Gastric carcinoma is one of the most prevalent malignancies. It remains the fifth most common malignancy and the fourth leading cause of cancer-related death globally (1), and it is typically diagnosed at an advanced stage. Fluoropyrimidine-based regimens combined with platinum have been widely used as first-line chemotherapeutic agents for gastric cancer treatment (2). The application of trastuzumab benefited advanced HER2-positive gastric cancer patients (3).

Several programmed death 1/programmed cell death-legend1 (PD-1/PD-L1) pathway inhibitors have been approved for various tumor malignancies. Immuno-oncological agents targeting PD-1 have shown promising results against several cancer types, such as malignant melanoma (4), non-small cell lung cancer (5), and oesophageal carcinoma (6). According to the results of the ATTRACTION-2 trial (7), nivolumab significantly improved the survival of AGC patients who received two or more lines of therapy. CheckMate 649 trials showed that in patients with strong PD-L1 positivity (CPS≥5), nivolumab plus chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in comparison with chemotherapy alone (8). Additionally, multiple anti-PD-1 therapy clinical trials are now underway or have been completed.

The introduction of immune checkpoint inhibitor (ICI) therapy has profoundly facilitated the development of therapeutic strategies for malignancies. However, for most gastric cancer patients, long-term efficacy cannot be maintained. Therefore, there is still the need for a reliable biomarker to find patients who derive a greater clinical benefit from immunotherapy. Previous research has suggested that gastric cancer with higher tumor mutation burden (TMB), high microsatellite instability (MSI-H), and Epstein-Barr virus (EBV)-positive status tends to prefer a therapeutic response to ICI therapy (9–11). However, a large number of patients benefit from a low tumor mutation burden, microsatellite stability (MSS), or EBV-negative state (12). Moreover, most biomarkers rely on tumor tissue testing, and the access and testing methods are complicated, which increases the invasive operation risk of patients. It is not easy to repeat testing. Therefore, convenient and straightforward inflammation indices as a part of prognostic cancer tools for AGC patients receiving anti-PD-1 therapy need to be explored and discovered.

Inflammation and inflammation-related factors are intricately linked to tumorigenesis (13, 14). Inflammatory factors have been suggested to be conducive to cancer initiation, progression, and metastasis (15, 16). Neutrophils are the most abundant white blood cells among circulating white blood cells and play a vital role in body immunity. In addition, neutrophils are also involved in the formation of the tumor microenvironment (17). Tumor-associated neutrophils (TANs) are related to tumor development and progression without eliciting immunosuppressive activity (18). Our team’s previous findings suggested that extracellular traps released by neutrophils are also markers of AGC (19). As another critical cell in the immune system, lymphocytes may contribute to weakening the inhibitory effect of tumor cell proliferation (20). Furthermore, blood platelets play an essential role in cancer metastasis, and their mechanism in cancer is still unknown (21).

The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are markers that reflect the systemic inflammatory burdens in patients. Multiple studies have proven the advantages of NLR and PLR as tumor biomarkers in diagnosis, curative effect evaluation, and prognosis monitoring in gastric cancer (22), non-small cell lung cancer (23), and malignant melanoma (24). Therefore, they may serve as biomarkers in response to ICI therapy. Previous studies have shown that the derived neutrophil-to-lymphocyte ratio (dNLR) and NLR have similar prognostic values in various types of cancer (25). In addition, serum baseline dNLR levels among non-small cell lung cancer patients can predict the efficacy of immunotherapy (26). Furthermore, SII (the systemic immune-inflammation index) has advantages over NLR and PLR in predicting the survival of AGC patients (27). In immunotherapy, previous research reported that the SII could not serve as an independent factor of the prognosis of PFS in patients with gastric cancer (28). The monocyte-to-lymphocyte ratio (MLR) was shown to be an independent factor of prognosis for PFS and OS in a study involving both advanced gastric and colorectal cancer patients who accepted anti-PD-1 therapy (29). Overall, the prognostic value of inflammatory marker levels in patients with AGC remains contentious and imperfect. In this retrospective study, we analyzed the correlation between NLR, PLR, MLR, dNLR, SII, and PFS, OS to explore the changes in inflammatory markers and prognostic value in AGC patients treated with anti-PD-1. The main endpoints of this research are PFS and OS.

Hence, the clinical research sought to determine whether the NLR, PLR, MLR, dNLR, and SII can be used as markers for patients with AGC receiving immunotherapy. Concretely, our goals are as follows: i) to evaluate the association between the level of inflammatory markers and clinical characteristics. ii) Comparison of baseline, optimal effect, changes in inflammatory markers when progression, and the association between inflammatory markers and short-term effects. iii) To assess the relationship between the levels of inflammatory
markers and the progression-free survival (PFS) and overall survival (OS) of patients with AGC. iv) To evaluate the correlation between the level of inflammatory markers and prognosis.

**MATERIALS AND METHODS**

**Patients and Data Collection**

The retrospective analysis included data from one hundred and six patients with AGC treated with anti-PD-1 therapy between 20 July 2019 and 16 March 2021, which was enrolled by the Department of Medical Oncology and oncology-related departments, the First Affiliated Hospital of Anhui Medical University. Additionally, this project was approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University. The clinical data were obtained from the electrical medical record system, where variables including age, sex, differentiation, primary tumor location, metastatic site, number of metastatic sites, number of prior treatments, performance of the Eastern Cooperative Oncology Group, first-line chemotherapeutic regimen, alcohol consumption, serum tumor markers, HER2 status when starting anti-PD-1 therapy and previous therapies. The tumor-node-metastasis (TNM) stage was assessed based on the AJCC 8th edition TNM classification system. The inclusion criteria were as follows: i) all patients were diagnosed with gastric adenocarcinoma by pathology; ii) patients with advanced or unresectable cancer. iii) the patients’ physical condition can tolerate anti-PD-1 treatment or chemotherapy; iv) complete clinical data. The exclusion criteria were as follows: i) the patients’ cases were related to acute or uncontrolled infectious diseases, rheumatic disease, or severe cardiovascular or cerebrovascular diseases; ii) patients with two or more primary malignant carcinomas or other species of pathology; iii) when combined chemotherapy occurs if bone marrow suppression occurs, data after using granulocyte colony-stimulating factor or recombinant human thrombopoietin.

**Evaluation of the Inflammatory Markers**

Patients underwent at least two cycles of immunotherapy, and peripheral blood samples were gathered up to two weeks before treatment. The samples were sonicated in a timely manner and centrifuged for 2 h. Venous blood (2 ml) was collected from the patient under fasting and resting states and injected into a vacuum anticoagulation tube containing dipotassium ethylenediaminetetraacetate (EDTA-K$_2$). Additionally, 3-4 ml venous blood was collected and injected into a separation-promoting gel tube. Patients’ routine blood and blood biochemical parameters were collected. Peripheral blood samples of absolute neutrophil counts (ANCs), lymphocyte counts (ALCs), monocyte counts (AMCs), and platelet counts were recorded to calculate inflammatory markers. The NLR was calculated as ANC/ALC. The PLR was calculated as platelet count/ALC. The MLR was calculated as AMC/ALC. The dNLR was calculated as ANC/(WBC-ANC). The SI was calculated as ANC×platelet count/ALC. Inflammation markers were then categorized by Youden’s index using receiver operating characteristic (ROC) analysis as the cut-off.

**Follow-Up**

Follow-up data were retrospectively obtained by the electrical clinical medical record system or telephone follow-up. To evaluate the therapeutic response, clinical evaluation and imaging examinations, including computed tomography (CT) scanning or other examinations needed, were performed every two courses or obvious clinical deterioration according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 or iRECIST. Clinical efficacy was evaluated by the researchers and defined as either complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), on the basis of RECIST version 1.1 or iRECIST. For patients with PD who were evaluated for the first time, we reaffirmed the exclusion of false progression. The objective response rate (ORR) was calculated by CR plus PR. The disease control rate (DCR) was calculated as CR and PR and SD. PFS was calculated from the date of the initial treatment with the anti-PD-1 agent to disease progression or death or the last follow-up. OS was calculated from the date of the initial treatment with the anti-PD-1 agent to death, or the last follow-up. In the research, the date cut-off for follow-up was 1 December 2021. Treatment persisted until disease progression, unacceptable toxicity, or consent withdrawal.

**Statistical Analyses**

Qualitative variables were compared between groups through the $\chi^2$ test or Fisher’s exact test. Inflammation markers were then categorized by Youden’s index using ROC analysis as the cut-off value. Kaplan–Meier methodology was used to construct survival curves to estimate the PFS and OS of patients. Univariate and multivariate Cox proportional hazards regression of prognostic factors were conducted, and the 95% confidence interval (CI) was given. Multivariable models were generated based on including all variables with p<0.05 on univariable survival analysis. The final models were determined using stepwise backward method elimination of any variables with p<0.05 in the multivariable analyses. For all tests, a two-sided P<0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism 8 (GraphPad Software, San Diego, CA) and SPSS version 22.0 (SPSS Inc., Chicago, IL, USA).

**RESULTS**

One hundred and six patients with AGC who underwent anti-PD-1 therapy were enrolled in this study, 53 patients in the first-line treatment, and 53 patients in the second-line or posterior line. The short-term effect was collected in all events. The number of PFS events was 81, 37 patients in first-line
treatment and 44 patients in second-line or posterior treatment. And the number of OS events was 60, 27 patients in first-line treatment and 33 patients in second-line or posterior-line treatment. There were no unanticipated serious adverse events or other diseases during the study. Inflammatory markers were then categorized by Youden’s index using ROC analysis as the cut-off value [NLR=3.11 (range 0.53–12.93), PLR=172.79 (range 28.28–542.86), MLR=0.20 (range 0.01–1.26), dNLR=2.09 (range 0.29–6.28), SII=1140.91 (range 31.67–4687.76)]. The median follow-up durations in AGC patients were enrolled in this research, including 72 males (67.9%) aged >65 years and 77 (72.6%) aged ≤65 years; 53 patients (50.0%) received first-line treatment, and 53 (50.0%) received second-line or posterior treatment. Data were collected on the differentiation of gastric cancer in 101 patients and on the location of tumorigenesis in 102 patients. Data were also collected on 105 LDH levels, 96 CEA levels, 96 CA199 levels, and 79 CA724 levels. 7 patients were HER2 positive, 67 were negative and 32 had unknown HER2 status. Statistically, NLR level was found to correlate significantly with peritoneal metastasis (P=0.039) and CEA level (P=0.034). Patients with poor differentiation AGC (P=0.009) had a higher percentage of higher MLR levels in plasma. And in the dNLR groups, significant differences were found in peritoneal metastasis (P=0.005). Additionally, the number of metastatic sites was significantly related to NLR level (P=0.039), MLR level (P=0.031), dNLR level (P=0.005), and SII level (P=0.020). However, there were no relationships between inflammatory markers and other clinicopathologic factors.

Baseline Characteristics
The characteristics of the patients are given in Table 1. One hundred and six patients with AGC who accepted anti-PD-1 therapy were enrolled in this research, including 72 males (67.9%) aged >65 years and 77 (72.6%) aged ≤65 years; 53 patients (50.0%) received first-line treatment, and 53 (50.0%) received second-line or posterior treatment. Data were collected on the differentiation of gastric cancer in 101 patients and on the location of tumorigenesis in 102 patients. Data were also collected on 105 LDH levels, 96 CEA levels, 96 CA199 levels, and 79 CA724 levels. 7 patients were HER2 positive, 67 were negative and 32 had unknown HER2 status. Statistically, NLR level was found to correlate significantly with peritoneal metastasis (P=0.039) and CEA level (P=0.034). Patients with poor differentiation AGC (P=0.009) had a higher percentage of higher MLR levels in plasma. And in the dNLR groups, significant differences were found in peritoneal metastasis (P=0.005). Additionally, the number of metastatic sites was significantly related to NLR level (P=0.039), MLR level (P=0.031), dNLR level (P=0.005), and SII level (P=0.020). However, there were no relationships between inflammatory markers and other clinicopathologic factors.

Analysis of Kaplan–Meier Survival Curves
Figure 3 shows the Kaplan–Meier curves of PFS and OS in the first-line therapy. The more than three metastatic sites group had a significantly shorter median PFS time than the less than three metastatic sites group (mPFS, 3.7 months, 95% CI: 2.564–4.836 vs. 8.8 months, 95% CI: 5.550–12.050, P<0.001) (Figure 3A). In comparison to the peritoneal metastasis negative group, the peritoneal metastasis positive group had a significantly poorer PFS time (mPFS, 6.4 months, 95% CI: 2.770–10.030 vs. 8.8 months, 95% CI: 5.011–12.589, P=0.008) (Figure 3B). Moreover, in contrast to the lung metastasis negative group, the lung metastasis positive group had a significantly poorer PFS time (mPFS, 3.7 months, 95% CI: 1.780–5.620 vs. 8.4 months, 95% CI: 6.272–10.528, P=0.038) (Figure 3C). Unfortunately, none of the inflammatory marker levels had significant differences in PFS in the first-line therapy. Similarly, more than three metastatic sites and positive peritoneal metastases had poorer OS compared to fewer than three metastatic sites and negative peritoneal metastases in the first-line therapy, (mOS, 6.7 months vs. 16.9 months, P=0.002) (Figure 3D), (mOS, 7.6 months, 95% CI: 3.621–11.579 vs. not reached, P=0.001) (Figure 3E), respectively. OS was shorter in patients with PLR>243.33 than in those with PLR ≤243.33 (mOS, 6.7 months, 95% CI: 0.963–12.437 vs. 20.7 months, 95% CI: 11.079–30.321, P=0.006) (Figure 3F). And compared to the MRL>0.20, patients with MRL ≤0.20 had a significantly longer OS (mOS, 12.8 months, 95% CI: 10.030–15.570 vs. not reached, P=0.028) (Figure 3G). Patients with low ECOG had a longer OS than those with high ECOG (mOS, 14.4 months vs. 3.6 months, P=0.021) (Figure 3H). Figure 4 shows the Kaplan–Meier curves of PFS in second-line or posterior therapy. PFS was worse in the more than three metastatic sites group than in the less than three metastatic sites group (mPFS, 2.2 months, 95% CI: 0.183–4.217 vs. 6.1 months, 95% CI: 5.162–7.038, P=0.003) (Figure 4A).
### TABLE 1 | Baseline clinical characteristics of AGC patients.

| Age (years)   | N (%)  | (n=61) | (n=45) | (n=84) | (n=22) | (n=84) | (n=60) | (n=46) | (n=85) | (n=21) |
|---------------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| ≤65           | 77 (72.6) | 43 | 34 | 0.563 | 60 | 17 | 0.584 | 15 | 62 | 0.598 | 43 | 34 | 0.797 | 60 | 17 | 0.340 |
| >65           | 29 (27.4) | 18 | 11 | 4 | 24 | 5 | 7 | 22 | 17 | 12 | 25 | 4 |
| Gender        |        |        |        |        |        |        |        |        |        |        |
| Male          | 72 (67.9) | 43 | 29 | 0.510 | 57 | 15 | 0.977 | 15 | 57 | 0.977 | 43 | 29 | 0.346 | 59 | 13 | 0.509 |
| Female        | 34 (32.1) | 18 | 16 | 27 | 7 | 7 | 27 | 17 | 17 | 26 | 8 |
| Differentiation |        |        |        |        |        |        |        |        |        |        |
| Poor          | 61 (60.4) | 32 | 29 | 0.079 | 49 | 12 | 0.785 | 8 | 53 | 0.009 | 33 | 28 | 0.180 | 48 | 13 | 0.427 |
| Moderate or Well | 40 (39.6) | 28 | 12 | 33 | 7 | 14 | 26 | 27 | 13 | 34 | 6 |
| Location      |        |        |        |        |        |        |        |        |        |        |
| Upper         | 35 (34.3) | 20 | 15 | 0.084 | 27 | 8 | 0.586 | 10 | 25 | 0.582 | 20 | 15 | 0.318 | 28 | 7 | 0.772 |
| Middle        | 21 (20.6) | 9 | 12 | 17 | 4 | 3 | 18 | 9 | 12 | 16 | 5 |
| Low           | 34 (33.3) | 25 | 9 | 30 | 4 | 6 | 28 | 23 | 11 | 29 | 5 |
| Others        | 12 (11.8) | 5 | 7 | 9 | 3 | 3 | 9 | 6 | 6 | 9 | 3 |
| Metastatic site |        |        |        |        |        |        |        |        |        |        |
| Peritoneal metastasis |     |        |        |        |        |        |        |        |        |        |
| Negative      | 77 (72.6) | 49 | 28 | 0.039 | 62 | 15 | 0.598 | 18 | 59 | 0.278 | 50 | 27 | 0.005 | 65 | 12 | 0.075 |
| Positive      | 29 (27.4) | 12 | 17 | 22 | 7 | 4 | 25 | 10 | 19 | 20 | 9 |
| Liver metastasis |        |        |        |        |        |        |        |        |        |        |
| Negative      | 64 (60.4) | 36 | 28 | 0.739 | 51 | 13 | 0.890 | 14 | 50 | 0.726 | 35 | 29 | 0.623 | 49 | 15 | 0.248 |
| Positive      | 42 (39.6) | 25 | 17 | 33 | 9 | 8 | 34 | 25 | 17 | 36 | 6 |
| Lymph node metastasis | | | | | | | | | | | |
| Negative      | 30 (28.3) | 18 | 12 | 0.748 | 23 | 7 | 0.681 | 6 | 24 | 0.904 | 18 | 12 | 0.658 | 26 | 4 | 0.293 |
| Positive      | 76 (71.7) | 43 | 33 | 61 | 15 | 16 | 60 | 42 | 34 | 59 | 17 |
| Lung metastasis |        |        |        |        |        |        |        |        |        |        |
| Negative      | 90 (84.9) | 53 | 37 | 0.507 | 70 | 20 | 0.515 | 19 | 71 | >0.999 | 52 | 38 | 0.563 | 73 | 17 | 0.517 |
| Positive      | 16 (15.1) | 8 | 8 | 14 | 2 | 3 | 13 | 8 | 8 | 12 | 4 |
| Number of metastatic sites | | | | | | | | | | | |
| ≤2           | 77 (72.6) | 49 | 28 | 0.039 | 63 | 14 | 0.287 | 20 | 57 | 0.031 | 50 | 27 | 0.005 | 66 | 11 | 0.020 |
| ≥3           | 29 (27.4) | 12 | 17 | 21 | 18 | 2 | 27 | 10 | 19 | 19 | 10 |
| ECOG PS       |        |        |        |        |        |        |        |        |        |        |
| 0-1          | 99 (93.4) | 59 | 40 | 0.132 | 77 | 22 | 0.340 | 21 | 78 | >0.999 | 58 | 41 | 0.235 | 81 | 18 | 0.138 |
| ≥2           | 7 (6.6) | 2 | 5 | 2 | 7 | 0 | 1 | 6 | 2 | 5 | 4 |
| First line chemotherapy | | | | | | | | | | | |
| Fluorouracil | 65 (61.3) | 40 | 25 | 0.426 | 50 | 15 | 0.695 | 14 | 51 | 0.571 | 41 | 24 | 0.146 | 51 | 14 | 0.773 |
| Fluorouracil + Platinum | | | | | | | | | | | |
| Fluorouracil + Taxanes | | | | | | | | | | | |
| Others       | 27 (25.5) | 15 | 12 | 23 | 4 | 4 | 23 | 14 | 13 | 23 | 4 |
| Response after chemotherapy | | | | | | | | | | | |
| CR+PR        | 24 (22.6) | 14 | 10 | 0.097 | 19 | 5 | >0.999 | 4 | 20 | 0.155 | 16 | 8 | 0.055 | 21 | 3 | 0.206 |
| SD           | 53 (50.0) | 35 | 18 | 42 | 11 | 15 | 38 | 33 | 20 | 44 | 9 |

(Continued)
TABLE 1 | Continued

| Total (n=106) | NLR≤3.11 (n=61) | NLR>3.11 (n=45) | P | PLR≤243.33 (n=84) | PLR>243.33 (n=22) | P | MLR≤0.20 (n=84) | MLR>0.20 (n=22) | P | dNLR≤2.09 (n=60) | dNLR>2.09 (n=46) | P | SII≤1140.91 (n=85) | SII>1140.91 (n=21) | P |
|--------------|----------------|----------------|---|-----------------|-----------------|---|-----------------|-----------------|---|-----------------|-----------------|---|-----------------|-----------------|---|
| PD           | 29 (27.4)      | 12 17          | 23 6 | 3 26            | 11 18           | 20 9 |
| Alcohol Consumption |
| Abstinence or low risk | 94 (88.7) | 54 40 | 0.963 73 21 | 0.453 20 74 | >0.999 53 41 | 0.898 76 18 | 0.701 |
| Hazardous or harmful |
| Drugs |
| Camrelizumab | 54 (50.9) | 31 23 | 0.137 47 7 | 0.086 13 41 | 0.602 31 23 | 0.717 46 8 | 0.216 |
| Sintilimab | 37 (34.9) | 22 15 | 0.034 27 10 | 0.200 7 30 | 0.135 21 4 | 0.089 34 9 | 0.313 |
| Toripalimab | 5 (4.7) | 5 1 | 4 1 | 0.4 1 | 0.1 0 | 0.2 0 | 0.2 0 |
| Pembrolizumab | 7 (6.6) | 2 5 | 0 2 | 0 7 | 3 4 | 4 3 |
| Nivolumab | 3 (2.8) | 1 2 | 1 2 | 1 2 | 1 2 | 2 1 |
| LDH |
| ≤250 | 75 (71.4) | 45 30 | 0.350 58 17 | 0.495 13 62 | 0.280 45 30 | 0.214 62 13 | 0.280 |
| >250 | 30 (28.6) | 15 15 | 25 5 | 8 22 | 0.137 21 16 | 0.16 22 8 |
| CEA |
| ≤5 | 43 (44.8) | 20 23 | 0.034 32 11 | 0.200 6 37 | 0.135 21 22 | 0.089 34 9 | 0.313 |
| >5 | 53 (55.2) | 36 17 | 45 8 | 14 39 | 35 18 | 46 7 |
| CA199 |
| ≤37 | 58 (60.4) | 37 21 | 0.180 48 10 | 0.640 14 44 | 0.508 37 21 | 0.180 51 7 | 0.074 |
| >37 | 38 (39.6) | 19 19 | 30 8 | 7 31 | 0.137 19 19 | 0.102 28 10 |
| CA724 |
| ≤8.2 | 60 (75.9) | 37 23 | 0.271 49 11 | 0.336 14 46 | 0.749 38 22 | 0.102 51 9 | 0.176 |
| >8.2 | 19 (24.1) | 9 10 | 13 6 | 3 16 | 8 11 | 13 6 |
| Molecular classification |
| HER negative | 72 (67.9) | 41 31 | 0.315 56 16 | 0.516 14 58 | 0.783 41 31 | >0.999 55 17 | 0.086 |
| HER positive | 7 (6.6) | 6 1 | 7 0 | 2 5 | 3 3 | 7 0 |
| Unknown | 27 (25.5) | 14 13 | 21 6 | 6 21 | 15 12 | 23 14 |
With respect to inflammatory makers, PFS was shorter in patients with PLR > 243.33, NLR > 3.11, dNLR > 2.09, and SII > 1140 than in those with PLR ≤ 243.33 (mPFS, 3.3 months, 95% CI: 2.070–4.530 vs. 6.1 months, 95% CI: 5.122–7.078, P=0.019) (Figure 3B); NLR ≤ 3.11 (mPFS, 2.8 months, 95% CI: 1.995–3.605 vs. 6.5 months, 95% CI: 5.457–7.543, P=0.041) (Figure 3D); dNLR ≤ 2.09 (mPFS, 2.8 months, 95% CI: 1.527–4.073 vs. 6.5 months, 95% CI: 5.367–7.633, P=0.012) (Figure 3E); and SII ≤ 1140 (mPFS, 2.8 months, 95% CI: 0.000–6.598 vs. 6.1 months, 95% CI: 5.151–7.049, P=0.027) (Figure 3F), respectively. Additionally, the low ECOG group had significantly longer PFS than the high ECOG group (mPFS, 5.8 months, 95% CI: 4.194–7.406 vs. 1.9 months, 95% CI: 1.041–2.759, P=0.030) (Figure 4C). Figure 5 shows the Kaplan–Meier curves of OS in second-line or posterior therapy. OS was worse in the group with more than three metastatic sites than in the group with less than three metastatic sites (mOS, 4.0 months, 95% CI: 2.232–5.768 vs. 10.9 months, 95% CI: 6.369–15.431, P=0.006; NLR: mOS, 4.0 months, 95% CI: 0.000–8.916 vs. 14.5 months, 95% CI: 8.506–20.494, P=0.001; dNLR: mOS, 8.3 months, 95% CI: 1.174–15.426 vs. 15.0 months, 95% CI: 8.911–21.089, P=0.001; SII: mOS, 3.2 months, 95% CI: 2.031–4.369 vs. 11.4 months, 95% CI: 6.946–15.854, P<0.001) (Figures 5C–F), respectively.

**Prognostic Value of Inflammatory Markers in AGC Patients**

For patients who accepted anti-PD-1 therapy in the first-line treatment, univariable and multivariate Cox regression analyses demonstrated only the number of metastatic sites (HR: 3.155, 95% CI: 1.601–6.216, P=0.001) was significantly correlated with PFS (Table 2). Nevertheless, no significant difference was observed in PFS within any other baseline clinical characteristic. In addition, both PLR level (HR: 2.770, 95% CI: 1.234–6.219, P=0.014) and peritoneal metastases (HR: 3.098, 95% CI: 1.446–6.634, P=0.004) were independent prognostic...
FIGURE 2 | Efficacy of anti-PD-1 treatment according to the changes in inflammatory markers in AGC patients in the ORR group (A–E), DCR group (F–J), and subgroup analysis groups (K–T). A: Levels of inflammatory markers in patients in the baseline. B: Levels of inflammatory markers in patients with optimal effects. C: Levels of inflammatory markers when disease progression.

FIGURE 3 | Kaplan–Meier curves of progression-free survival (PFS) and overall survival (OS) in the first-line treatment according to PFS: metastatic sites (A), peritoneal metastasis (B), lung metastasis (C), OS: metastatic sites (D), peritoneal metastasis (E), PLR (F), MLR (G), and ECOG PS (H) at baseline. The P values were calculated using the log-rank test (two-sided).
predictors for GC patients with OS according to Cox regression analyses (Table 3). In second-line or posterior therapy, PLR level, ECOG PS, and number of metastatic sites were independent factors of prognosis for PFS in AGC patients depending on univariate and multivariate COX regression analysis (HR: 2.682, 95% CI: 1.083–6.639, P=0.033; HR: 3.595, 95% CI: 1.348–9.588, P=0.011; HR: 2.751, 95% CI: 1.324–5.714, P=0.007) (Table 4), respectively. With respect to OS in second-line or posterior therapy, patients with baseline NLR>3.11 had a shorter OS than those with NLR ≤ 3.11 (HR: 4.474, 95% CI: 1.942–10.308, P<0.001) (Table 5). The number of metastatic sites and differentiation were also independent factors of prognosis for OS in AGC patients (HR: 3.789, 95% CI: 1.590–9.028, P=0.003; HR: 0.398, 95% CI: 0.173–0.916, P=0.030) (Table 5).

**DISCUSSION**

Although immunotherapy has been changing the landscape of oncologic therapies, there is still a lack of biomarkers that can assess therapeutic responses and predict prognosis. Previous studies reported that immunotherapy efficacy is related to...
| TABLE 2 | Univariate and multivariate analysis of factors according to PFS in AGC patients treated with anti-PD-1 drugs in the first-line therapy. |
|---------------------------------|----------------|----------------|----------------|----------------|
| **Univariate analysis**         | **Multivariate analysis** |
| **HR (95% CI)**                 | **P value** | **HR (95% CI)** | **P value** |
| **Age (years)**                 |               |                |               |                |
| ≤65                             | 1 (reference) | 0.694          | –             | –              |
| >65                             | 1.183 (0.513-2.728) | 0.694 | –             | –              |
| **Gender**                      |               |                |               |                |
| Male                            | 1 (reference) |                | –             | –              |
| Female                          | 0.964 (0.506-1.918) | 0.964 | –             | –              |
| **Differentiation**             |               |                |               |                |
| Poor                            | 1 (reference) |                | –             | –              |
| Moderate or well                | 0.731 (0.342-1.562) | 0.416 | –             | –              |
| **Location**                    |               |                |               |                |
| Upper                           |                | 0.355          | –             | –              |
| Middle                          | 2.225 (0.906-5.464) | 0.081 | –             | –              |
| Low                             | 1.615 (0.880-3.839) | 0.278 | –             | –              |
| Others                          | 1.356 (0.429-4.284) | 0.603 | –             | –              |
| **Metastatic site**             |               |                |               |                |
| **Peritoneal metastasis**       |               |                |               |                |
| Negative                        | 1 (reference) |                | 1.448 (0.638-3.287) | 0.376 |
| Positive                        | 2.417 (1.236-4.731) | 0.008 | –             | –              |
| **Liver metastasis**            |               |                |               |                |
| **Negative**                    | 1 (reference) |                | –             | –              |
| **Positive**                    | 1.714 (0.870-3.777) | 0.116 | –             | –              |
| **Lymph node metastasis**       |               |                |               |                |
| **Negative**                    | 1 (reference) |                | –             | –              |
| **Positive**                    | 0.833 (0.378-1.835) | 0.650 | –             | –              |
| **Lung metastasis**             |               |                |               |                |
| **Negative**                    | 1 (reference) |                | 1.617 (0.633-4.131) | 0.315 |
| **Positive**                    | 2.512 (1.016-6.209) | 0.039 | –             | –              |
| **Number of metastatic sites**  |               |                |               |                |
| ≤2                              | 1 (reference) | <0.001         | 3.155 (1.601-6.216) | 0.001 |
| ≥3                              | 3.155 (1.601-6.216) | <0.001 | –             | –              |
| **ECOG PS**                     |               |                |               |                |
| 0-1                             | 1 (reference) |                | –             | –              |
| ≥2                              | 2.901 (0.884-12.312) | 0.130 | –             | –              |
| **First line chemotherapeutic regimen** |           |                |               |                |
| Fluorouracil+Platinum           | 1 (reference) |                | –             | –              |
| Fluorouracil+Taxanes            | 1.142 (0.394-3.306) | 0.807 | –             | –              |
| Others                          | 1.707 (0.809-3.602) | 0.160 | –             | –              |
| **Alcohol Consumption**         |               |                |               |                |
| Abstinence or low risk           | 1 (reference) |                | –             | –              |
| Hazardous or harmful            | 1.097 (0.426-2.821) | 0.848 | –             | –              |
| **NLR**                         |               |                |               |                |
| ≤3.11                           | 1 (reference) |                | –             | –              |
| >3.11                           | 1.627 (0.853-3.103) | 0.136 | –             | –              |
| **PLR**                         |               |                |               |                |
| ≤243.33                         | 1 (reference) |                | –             | –              |
| >243.33                         | 1.987 (0.973-4.057) | 0.055 | –             | –              |
| **MLR**                         |               |                |               |                |
| ≤0.20                           | 1 (reference) |                | –             | –              |
| >0.20                           | 1.958 (0.814-4.707) | 0.126 | –             | –              |
| **dNLR**                        |               |                |               |                |
| ≤2.09                           | 1 (reference) |                | –             | –              |
| >2.09                           | 1.694 (0.888-3.232) | 0.106 | –             | –              |
| **SII**                         |               |                |               |                |
| ≤1140.91                        | 1 (reference) |                | –             | –              |
| >1140.91                        | 1.812 (0.853-3.848) | 0.117 | –             | –              |
| **LDH**                         |               |                |               |                |
| ≤250                            | 1 (reference) |                | –             | –              |
| >250                            | 1.167 (0.561-2.429) | 0.679 | –             | –              |
| **CEA**                         |               |                |               |                |
| ≤5                              | 1 (reference) |                | –             | –              |
| >5                              | 0.746 (0.354-1.571) | 0.439 | –             | –              |

(Continued)
HER2 expression, MMR state, EBV state, and PD-L1 expression (9–11). However, most biomarkers are too expensive and complicated for patients. Thus, convenient and straightforward inflammation markers need to be discovered. The tumorigenesis and development of cancers are closely related to inflammation (13). Inflammatory markers have been reported to reflect the biological characteristics of AGC (30). The NLR, PLR, MLR, dNLR, and SII are prognostic markers that have been used to predict the outcome of immunotherapy in non-small cell lung cancer (31) and renal cancer (32). However, there is little information about the application of inflammatory markers in patients with AGC receiving anti-PD-1 treatment.

In our study, none of the inflammatory markers corresponded precisely to clinicopathologic factors. We found that peritoneal dissemination was associated with high levels of NLR and dNLR in patients with AGC at baseline. It is generally known that the peritoneum is the most frequent metastatic site for AGC, which often predicts poor prognosis (33). Similarly, Patients with more than three metastatic sites are related to high levels of NLR, MLR, dNLR, and SII, which is comparable to the results of previous studies (22). The outcome indirectly suggested that high levels of inflammatory markers might be associated with poor prognosis in AGC patients. Additionally, a high MLR is related to poor differentiation. At present, the MLR has been reported as a marker in advanced gastric and colorectal cancer patients treated with ICIs for the efficacy of DCR and an independent prognostic factor (29).

Although changes in inflammatory markers can reflect the patients’ response to treatment (34), few studies have reported dynamic changes in inflammatory markers in patients with AGC who underwent anti-PD-1 treatment. In our research, we discovered that inflammatory markers were closely associated with short-term efficacy in patients with AGC accepting anti-PD-1 treatment. Although only one patient achieved CR, four inflammatory markers declined after immunotherapy. This change also happened in the PR and SD groups. In the PR group, we found that NLR, PLR, dNLR, and SII levels decreased significantly in patients who achieved the optimal effect. In the SD state, this trend was also observed among NLR, dNLR, and SII. Additionally, similar downward trends were also noticed in ORR and DCR groups with NLR, PLR, dNLR, and SII. In particular, significant decreases in NLR, dNLR, and SII were observed among the PR, SD, ORR, and DCR groups after anti-PD-1 therapy. The outcome suggested that inflammation markers, especially SII, may be involved in the associated short-term efficacy. The SII appears to have more advantages than the NLR, PLR, and other inflammatory markers in AGC patients accepting anti-PD-1 therapy in predicting short-term efficacy, which might be because the SII combines several blood cell counts, reduces errors, and can reflect the balance between host inflammation and the immune response more comprehensively and objectively. Similarly, a significant decrease in SII was also observed after neoadjuvant chemotherapy in patients with gastric cancer (30). Notably, the bone marrow toxicity of neutrophils may change due to chemotherapy, which may affect the results. In our study, a significant decline in inflammatory markers in the PR and SD groups did not appear in the PD group. This suggested that the decline in inflammatory markers might be based on changes in short-term efficacy without interference from bone marrow suppression.

To our knowledge, our research is the first to show that AGC patients who underwent anti-PD-1 therapy with a higher baseline SII level had worse short-term effects than patients who had a lower SII level. However, SII, which has a curative effect evaluation value in the short-term curative effect, did not show statistical significance in PFS or OS according to multivariate Cox regression analyses. This situation may be due to many factors influencing the conversion of recent tumor control to prolonged survival and the limited sample size. Additionally, a significant decrease was also noticed in the PR, SD, ORR, and DCR groups with NLR and dNLR. These results are in accordance with previous reports that enrolled patients with both advanced gastric and colorectal cancer (29). To further explore the changes in inflammatory markers in PD patients, we compared the levels of inflammatory markers in patients receiving immunotherapy with baseline and disease progression and with optimal efficacy and disease progression. Interestingly, baseline inflammatory marker levels in AGC patients all tended to rise when immunotherapy failed, but only MLR was statistically significantly elevated. Furthermore, NLR, MLR, dNLR, and SII were significantly increased in AGC patients during disease progression compared to optimal efficacy, which echoes the results of a previous study exploring changes in NLR before and after immunotherapy (35). Taken together, the outcomes

| Molecular classification | HR (95% CI) | P value | HR (95% CI) | P value |
|--------------------------|------------|---------|------------|---------|
| CA199                    |            |         |            |         |
| ≤27                      | 1 (reference) | 0.903   | –          | –       |
| >27                      | 1.048 (0.494-2.224) | 0.903   | –          | –       |
| CA724                    |            |         |            |         |
| ≤8.2                     | 1 (reference) | 0.903   | –          | –       |
| >8.2                     | 0.858 (0.352-2.090) | 0.736   | –          | –       |
| HER negative             |            |         |            |         |
| HER positive             | 0.973 (0.296-3.207) | 0.965   | –          | –       |
| Unknown                  | 1.067 (0.441-2.582) | 0.886   | –          | –       |
|                          | Univariate analysis |           | Multivariate analysis |           |
|--------------------------|---------------------|-----------|-----------------------|-----------|
|                          | HR (95% CI)         | P value   | HR (95% CI)           | P value   |
| **Age (years)**          |                     |           |                       |           |
| ≤65                      | 1 (reference)       | 0.149     | –                     | –         |
| >65                      | 1.883 (0.786-4.513) | 0.149     | –                     | –         |
| **Gender**               |                     |           |                       |           |
| Male                     | 1 (reference)       | 0.969     | –                     | –         |
| Female                   | 0.988 (0.451-2.151) | 0.969     | –                     | –         |
| **Differentiation**      |                     |           |                       |           |
| Poor                     | 1 (reference)       | 0.231     | –                     | –         |
| Moderate or well         | 0.553 (0.207-1.477) | 0.231     | –                     | –         |
| **Location**             |                     |           |                       |           |
| Upper                    | 1 (reference)       | 0.253     |                       |           |
| Middle                   | 2.652 (0.912-7.707) | 0.073     | –                     | –         |
| Low                      | 1.134 (0.410-3.134) | 0.808     | –                     | –         |
| Others                   | 1.238 (0.318-4.820) | 0.758     | –                     | –         |
| **Metastatic site**      |                     |           |                       |           |
| Peritoneal metastasis    |                     |           |                       |           |
| Negative                 | 1 (reference)       | 0.001     | 1 (reference)         | 0.004     |
| Positive                 | 3.244 (1.517-6.936) | 0.001     | 3.098 (1.446-6.634)   | 0.004     |
| Liver metastasis         |                     |           |                       |           |
| Negative                 | 1 (reference)       | 0.313     | –                     | –         |
| Positive                 | 1.486 (0.685-3.221) | 0.313     | –                     | –         |
| Lymph node metastasis    |                     |           |                       |           |
| Negative                 | 1 (reference)       | 0.105     | –                     | –         |
| Positive                 | 0.507 (0.220-1.171) | 0.105     | –                     | –         |
| Lung metastasis          |                     |           |                       |           |
| Negative                 | 1 (reference)       | 0.781     |                       |           |
| Positive                 | 1.163 (0.401-3.369) | 0.781     | –                     | –         |
| **Number of metastatic sites** |   |           |                       |           |
| ≤2                       | 1 (reference)       | 0.002     | 1 (reference)         | 0.644     |
| ≥3                       | 3.192 (1.482-6.874) | 0.002     | 1.296 (0.433-3.881)   | 0.644     |
| **ECOG PS**              |                     |           |                       |           |
| 0-1                      | 1 (reference)       | 0.022     | 1 (reference)         | 0.155     |
| ≥2                      | 4.829 (1.092-21.350)| 0.022     | 3.200 (0.643-15.925)  | 0.155     |
| **First line chemotherapeutic regimen** |               |           |                       |           |
| Fluorouracil+Platinum    | 1 (reference)       | 0.394     | –                     | –         |
| Fluorouracil+Taxanes     | 0.974 (0.222-4.265) | 0.972     | –                     | –         |
| Others                   | 1.775 (0.754-4.177) | 0.189     | –                     | –         |
| **Alcohol Consumption**  |                     |           |                       |           |
| Abstinence or low risk   | 1 (reference)       | 0.448     | –                     | –         |
| Hazardous or harmful     | 0.629 (0.187-2.108) | 0.448     | –                     | –         |
| **NLR**                  |                     |           |                       |           |
| ≤3.11                    | 1 (reference)       | 0.182     | –                     | –         |
| >3.11                    | 1.679 (0.778-3.625) | 0.182     | –                     | –         |
| **PLR**                  |                     |           |                       |           |
| ≤243.33                  | 1 (reference)       | 0.006     | 1 (reference)         | 0.014     |
| >243.33                  | 2.959 (1.318-6.642) | 0.006     | 2.770 (1.234-6.219)   | 0.014     |
| **MLR**                  |                     |           |                       |           |
| ≤0.20                    | 1 (reference)       | 0.028     | 1 (reference)         | 0.179     |
| >0.20                    | 4.385 (1.036-18.569)| 0.028     | 2.777 (0.626-12.311)  | 0.179     |
| **dNLR**                 |                     |           |                       |           |
| ≤2.09                    | 1 (reference)       | 0.136     | –                     | –         |
| >2.09                    | 1.781 (0.825-3.842) | 0.136     | –                     | –         |
| **SII**                  |                     |           |                       |           |
| ≤1140.91                 | 1 (reference)       | 0.098     | –                     | –         |
| >1140.91                 | 1.947 (0.873-4.346) | 0.098     | –                     | –         |
| **LDH**                  |                     |           |                       |           |
| ≤250                     | 1 (reference)       | 0.680     | –                     | –         |
| >250                     | 1.191 (0.520-2.726) | 0.680     | –                     | –         |
| **CEA**                  |                     |           |                       |           |
| ≤5                       | 1 (reference)       | 0.258     | –                     | –         |
| >5                       | 0.591 (0.235-1.487) | 0.258     | –                     | –         |

(Continued)
suggested that NLR, MLR, dNLR, as well as SII, can predict the progression of the disease for patients receiving anti-PD-1 treatment. The dynamic changes in inflammatory markers may imply the impact of anti-PD-1 therapy on the immune system.

In this research, the baseline levels of inflammatory markers were not related to PFS in the first-line therapy. This situation is associated with many factors that might affect the prognosis and survival of patients receiving first-line therapy. However, the prognosis of patients with fewer than three metastatic sites significantly outperformed that of patients with more than three metastatic sites, according to the multivariate Cox analysis. Additionally, both peritoneal metastasis positive and high PLR level were independent factors of prognosis for short OS in AGC patients by multivariate Cox regression analyses. Interestingly, previous clinical trials have reported that the outcome of AGC patients receiving PD-1 inhibitor monotherapy with peritoneal metastasis negative or fewer metastatic sites is significantly better than those of patients with peritoneal metastasis positive or more metastatic sites (36). Our study obtained similar results according to peritoneal metastasis positive and more metastatic sites for poorer prognosis. In second-line or posterior therapy, the number of metastatic sites, ECOG PS, and PLR level were independent factors of prognosis for short OS in AGC patients by multivariate Cox regression analyses. Therefore, patients with fewer metastatic sites had significantly better OS than those with more metastatic sites. However, in our study, HER2 status was not an independent factor affecting the prognosis of patients with progressive gastric cancer receiving immunotherapy, which may be related to the fact that immunotherapy significantly improved the prognosis of patients with HER2-negative gastric cancer, compensating for the pre-existing survival differences across HER2 status. Notably, previous reports indicated that the PLR can serve as an independent prognostic factor for patients receiving ICI treatment in non-small cell lung (23) and malignant melanoma (39), which corresponded to our results. To the best of our knowledge, this is the first report that a high baseline PLR is an independent predictor of poor PFS in the second-line or posterior therapy and poor OS in first-line therapy in AGC patients receiving anti-PD-1 therapy, which further enriches the application value of inflammatory markers in immunotherapy.

At present, the potential mechanism of PLR in anti-PD-1 therapy is not fully understood. As studies have shown, malignant tumors are often accompanied by platelet rise and aggregation. Reducing the number of platelets or inhibiting the function of platelets inhibits the metastasis of tumor cells (21). The reasons for this phenomenon are multifocal. First, platelets can promote the formation of tumor thrombi and protect tumor cells from the blood flow shear force of blood flow and NK cell lysis (40). Second, platelets have been identified as a major source of basic fibroblast growth factor (bFGF) and transforming growth factor-β (TGF-β), promoting tumor growth (41). Third, platelets can enhance the invasion potential of tumor cells. Studies have shown that circulating tumors (CTCs) activate platelet secretion of TGF-β, which induces platelets to accelerate or maintain CTC epithelial-mesenchymal transition (EMT) to promote abscission, migration, and invasion of tumor cells from the primary site (42). Blocking the TGF-β signaling pathway might attenuate tumor extravasation and pulmonary metastasis (43). Platelets bound by tumor cells release soluble media, such as ADP, thromboxane A2 (TXA2), or high mobility group 1 (HMGB1), which are linked to Toll-like receptor 4 (TLR4) on platelets and mediate platelet-tumor cell interactions, which increase the permeability of the blood vessel wall, thereby promoting the metastasis of tumor cells (44). Additionally, platelets also play an essential role in promoting the adhesion, retention, and metastasis of cancer cells in blood vessels, and current studies have shown that the molecules that mediate platelet adhesion function are mainly p-selectin and integrin αIIBβ3 expressed on the surface of activated platelets. Blocking p-selectin or αIIBβ3 integrin with antibodies significantly reduces platelet interactions with tumor cells (45).
| TABLE 4 | Univariate and multivariate analysis of factors according to PFS in AGC patients treated with anti-PD-1 drugs in the second-line or posterior therapy. |
| Univariate analysis | Multivariate analysis |
|---------------------|---------------------|
| HR (95% CI) | P value | HR (95% CI) | P value |
| **Age (years)** | | | | |
| ≤65 | 1 (reference) | | | |
| >65 | 0.944 (0.492-1.814) | 0.863 | | |
| **Gender** | | | | |
| Male | 1 (reference) | | | |
| Female | 1.227 (0.629-2.394) | 0.547 | | |
| **Differentiation** | | | | |
| Poor | 1 (reference) | | | |
| Moderate or well | 0.924 (0.495-1.725) | 0.805 | | |
| **Location** | | | | |
| Upper | 1 (reference) | 0.707 | | |
| Middle | 1.272 (0.542-2.983) | 0.581 | | |
| Low | 1.157 (0.532-2.515) | 0.713 | | |
| Others | 1.741 (0.675-4.490) | 0.251 | | |
| **Metastatic site** | | | | |
| Peritoneal metastasis | | | | |
| Negative | 1 (reference) | | | |
| Positive | 1.293 (0.635-2.633) | 0.477 | | |
| Liver metastasis | | | | |
| Negative | 1 (reference) | | | |
| Positive | 1.580 (0.847-2.947) | 0.147 | | |
| Lymph node metastasis | | | | |
| Negative | 1 (reference) | | | |
| Positive | 1.231 (0.661-2.922) | 0.512 | | |
| Lung metastasis | | | | |
| Negative | 1 (reference) | | | |
| Positive | 1.172 (0.558-2.461) | 0.675 | | |
| **Number of metastatic sites** | | | | |
| ≤2 | 1 (reference) | 2.762 (1.358-5.618) | 0.004 | 2.751 (1.324-5.714) | 0.007 |
| ≥3 | | | | |
| **ECOG PS** | | | | |
| 0-1 | 1 (reference) | 2.712 (1.048-7.017) | 0.032 | 3.595 (1.348-9.588) | 0.011 |
| ≥2 | | | | |
| **First line chemotherapeutic regimen** | | | | |
| Fluorouracil+Platinum | 1 (reference) | 0.558 | | |
| Fluorouracil+Taxanes | 1.007 (0.432-2.351) | 0.987 | | |
| Others | 1.434 (0.723-2.846) | 0.302 | | |
| **Alcohol Consumption** | | | | |
| Abstinence or low risk | 1 (reference) | 0.938 (0.333-2.639) | 0.904 | | |
| Hazardous or harmful | | | | |
| **NLR** | | | | |
| ≤3.11 | 1 (reference) | 1.883 (1.009-3.514) | 0.044 | 1.639 (0.809-3.319) | 0.170 |
| >3.11 | | | | |
| **PLR** | | | | |
| ≤243.33 | 1 (reference) | 2.716 (1.127-6.543) | 0.020 | 2.682 (1.083-6.639) | 0.033 |
| >243.33 | | | | |
| **MLR** | | | | |
| ≤0.20 | 1 (reference) | 1.497 (0.712-3.146) | 0.284 | | |
| >0.20 | | | | |
| **dNLR** | | | | |
| ≤2.09 | 1 (reference) | 2.168 (1.165-4.035) | 0.012 | 1.268 (0.395-4.073) | 0.690 |
| >2.09 | | | | |
| **SII** | | | | |
| ≤1140.91 | 1 (reference) | 2.356 (1.070-5.188) | 0.028 | 0.765 (0.215-2.718) | 0.679 |
| >1140.91 | | | | |
| **LDH** | | | | |
| ≤250 | 1 (reference) | 1.288 (0.663-2.500) | 0.454 | | |
| >250 | | | | |
| **CEA** | | | | |
| ≤5 | 1 (reference) | 1.879 (0.991-3.564) | 0.050 | | |
| >5 | | | | |

(Continued)
### TABLE 4 | Continued

|                        | Univariate analysis | Multivariate analysis |
|------------------------|---------------------|-----------------------|
|                        | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| **CA199**              |                     |                       |                     |                       |
| ≤27                    | 1 (reference)       |                       |                     |                       |
| >27                    | 1.038 (0.562-1.920) | 0.904                 | –                    | –                     |
| **CA724**              |                     |                       |                     |                       |
| ≤8.2                   | 1 (reference)       |                       |                     |                       |
| >8.2                   | 2.087 (0.919-4.737) | 0.072                 | –                    | –                     |
| **Molecular classification** |                 |                       |                     |                       |
| HER negative           | 1 (reference)       |                       |                     |                       |
| HER positive           | 1.448 (0.336-6.235) | 0.619                 | –                    | –                     |
| Unknown                | 1.705 (0.907-3.207) | 0.098                 | –                    | –                     |

### TABLE 5 | Univariate and multivariate analysis of factors according to OS in AGC patients treated with anti-PD-1 drugs in the second-line or posterior therapy.

|                        | Univariate analysis | Multivariate analysis |
|------------------------|---------------------|-----------------------|
|                        | HR (95% CI)         | P value               | HR (95% CI)         | P value               |
| **Age (years)**        |                     |                       |                     |                       |
| ≤65                    | 1 (reference)       |                       |                     |                       |
| >65                    | 0.958 (0.453-2.026) | 0.911                 | –                    | –                     |
| **Gender**             |                     |                       |                     |                       |
| Male                   | 1 (reference)       |                       |                     |                       |
| Female                 | 1.575 (0.718-3.455) | 0.254                 | –                    | –                     |
| **Differentiation**    |                     |                       |                     |                       |
| Poor                   | 1 (reference)       |                       |                     |                       |
| Poor                   | 0.424 (0.200-0.901) | 0.022                 | 0.398 (0.173-0.916) | 0.030                 |
| Location               |                     | 0.348                 |                       |                       |
| Upper                  | 1 (reference)       |                       |                     |                       |
| Middle                 | 2.452 (0.905-6.649) | 0.078                 | –                    | –                     |
| Low                    | 1.540 (0.595-3.984) | 0.373                 | –                    | –                     |
| Others                 | 1.769 (0.555-5.643) | 0.335                 | –                    | –                     |
| **Metastatic site**    |                     |                       |                     |                       |
| Peritoneal metastasis  |                     |                       |                     |                       |
| Negative               | 1 (reference)       |                       |                     |                       |
| Positive               | 2.192 (0.970-4.954) | 0.053                 | –                    | –                     |
| Liver metastasis       |                     |                       |                     |                       |
| Negative               | 1 (reference)       |                       |                     |                       |
| Positive               | 0.617 (0.303-1.257) | 0.180                 | –                    | –                     |
| Lymph node metastasis  |                     |                       |                     |                       |
| Negative               | 1 (reference)       |                       |                     |                       |
| Positive               | 1.971 (0.943-4.119) | 0.067                 | –                    | –                     |
| Lung metastasis        |                     |                       |                     |                       |
| Negative               | 1 (reference)       |                       |                     |                       |
| Positive               | 0.494 (0.172-1.423) | 0.183                 | –                    | –                     |
| Number of metastatic sites |                     |                       |                     |                       |
| ≤2                     | 1 (reference)       |                       |                     |                       |
| ≥3                     | 2.792 (1.321-5.901) | 0.005                 | 3.789 (1.590-9.028) | 0.003                 |
| **ECOG PS**            |                     |                       |                     |                       |
| 0-1                    | 1 (reference)       |                       |                     |                       |
| ≥2                     | 2.652 (0.912-7.715) | 0.063                 | –                    | –                     |
| **First line chemotherapeutic regimen** |                 |                       |                     |                       |
| Fluorouracil+Platinum  | 1 (reference)       |                       |                     |                       |
| Fluorouracil+Taxanes   | 1.659 (0.632-4.350) | 0.304                 | –                    | –                     |
| Others                 | 1.537 (0.681-3.469) | 0.301                 | –                    | –                     |
| Alcohol Consumption    |                     |                       |                     |                       |
| Abstinence or low risk  | 1 (reference)       |                       |                     |                       |
| Hazardous or harmful   | 1.252 (0.375-4.176) | 0.714                 | –                    | –                     |
| **NLR**                |                     |                       |                     |                       |
| ≤3.11                  | 1 (reference)       |                       |                     |                       |
| >3.11                  | 3.225 (1.542-6.744) | 0.001                 | 4.474 (1.942-10.308) | <0.001                |

(Continued)
summary, a higher PLR could serve as an indicator of poorer clinical outcomes in anti-PD-1 therapy, which provides new insights for future research.

Nevertheless, this study is limited by being a single-center retrospective study, which might result in selection biases and confounders. Thus, further prospective studies are required to support the use of inflammatory markers as prognostic factors for AGC patients treated with anti-PD-1 therapy. Consequently, there is still a larger sample size and an extended follow-up to confirm the conclusions.

**CONCLUSIONS**

In summary, peritoneal dissemination was significantly associated with high levels of NLR and dNLR in patients with AGC at baseline. Additionally, more than three metastatic sites was more frequent in AGC patients accepting anti-PD-1 therapy with high levels of NLR, MLR, dNLR, and SII. The decrease in NLR, PLR, MLR, dNLR, and SII levels was associated with better short-term efficacy of immunotherapy. For patients with optimal efficacy, elevated NLR, MLR, dNLR, and SII levels often indicate disease progression. And elevated baseline MLR level is also indicative of disease progression. High PLR level is a poor independent prognostic factor that affects PFS in the second-line or posterior therapy and OS in the first-line therapy with AGC patients receiving immunotherapy. Furthermore, NLR and histological differentiation were independent prognostic factors for OS in the second-line or posterior therapy. The number of metastatic sites and peritoneal metastases were significantly associated with the prognosis of AGC patients who received immunotherapy. Alternatively, ECOG≥2 is a poor prognostic factor for PFS in AGC patients receiving second-line or posterior immunotherapy. Our findings can further screen AGC patients who benefit from immunotherapy and are useful for treatment decisions in clinical practice.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article-supplementary material. Further inquiries can be directed to the corresponding authors.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the Ethics Committee of the First Affiliated Hospital of Anhui Medical University. The patients/participants provided their written informed consent to participate in this study.
AUTHOR CONTRIBUTIONS

KG and YZ planned and designed the study. ZQ, QW, and HW collected and analyzed the data and wrote the article. YJ, ML, WW, and YL helped to collect data. ZZ and TZ helped to analyze collected and analyzed the data and wrote the article. YJ, ML, KG and YZ planned and designed the study. ZQ, QW, and HW helped to collect data. ZZ and TZ helped to analyze collected and analyzed the data and wrote the article. YJ, ML, KG and YZ planned and designed

REFERENCES

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–49. doi: 10.3322/caac.21660

2. Kang Y-K, Chin K, Chung HC, Kadowski S, Oh SC, Nakayama N, et al. S-1 Plus Leucovorin and Oxaliplatin Versus S-1 Plus Cisplatin as First-Line Therapy in Patients With Advanced Gastric Cancer (SOLAR): A Randomised, Open-Label, Phase 3 Trial. Lancet Oncol (2020) 21:1045–56. doi: 10.1016/S1470-2045(20)30315-6

3. Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab Versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. Lancet (2010) 376:687–97. doi: 10.1016/s0140-6736(10)61211-x

4. Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Adjuvant Pembrolizumab Versus Placebo in Resected Stage III Melanoma. N Engl J Med (2018) 378:1789–901. doi: 10.1056/NEJMoa1802357

5. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Cooi J, Falop A, et al. Pembrolizumab Versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med (2016) 375:1823–33. doi: 10.1056/NEJMoa1607744

6. Huang J, Xu J, Chen Y, Zhuang W, Zhang Y, Chen Z, et al. Camrelizumab Versus Investigator’s Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCORT): A Multicentre, Randomised, Open-Label, Phase 3 Study. Lancet Oncol (2020) 21:832–42. doi: 10.1016/s1470-2045(20)30110-8

7. Kang Y-K, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet (2017) 390:2461–71. doi: 10.1016/s0140-6736(17)31827-5

8. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-Line Nivolumab Plus Chemotherapy Versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 459): A Randomised, Open-Label, Phase 3 Trial. Lancet (2021) 398:397–407. doi: 10.1016/s1470-2045(21)00797-2

9. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, Efficacy and Tumor Mutational Burden as a Biomarker of Overall Survival Benefit in Chemo-Refractory Gastric Cancer Treated With Toripalimab, a PD-1 Antibody in Phase Ib/II Clinical Trial NCT02915432. Ann Oncol (2019) 30:1479–86. doi: 10.1093/annonc/mdz197

10. Panda A, Mehnert JM, Hirshfield KM, Riedlinger G, Damare M, Saunders T, et al. Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer. J Natl Cancer Inst (2018) 110:316–20. doi: 10.1093/jnci/djx213

11. Mishima S, Kawaozoe A, Nakamura Y, Sasaki A, Kato D, Kuboki Y, et al. Clinicalopathological and Molecular Features of Responders to Nivolumab for Patients With Advanced Gastric Cancer. J Immunother Cancer (2019) 7:293. doi: 10.2147/jimm.2019.06.025

12. Kim ST, Cristescu R, Bass AJ, Kim KM, Odegaard JJ, Kim K, et al. Comprehensive Molecular Characterization of Clinical Responses to PD-1 Inhibition in Metastatic Gastric Cancer. Nat Med (2018) 24:1449–58. doi: 10.1038/s41591-018-0101-z

13. Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity (2019) 51:27–41. doi: 10.1016/j.immuni.2019.06.025

FUNDING

This study was supported by grants from the National Science Foundation of Anhui Province (No. 1908085QH333), the Key Research and Development Project of Anhui Province (No. 20200407020044), and the Natural Science Research Project of Anhui Provincial University (No. KJ2018ZD019).
31. Bauckneht M, Genova C, Rossi G, Rijavec E, Dal Bello MG, Ferrarazzo G, et al. The Role of the Immune Metabolic Prognostic Index in Patients With Non-Small Cell Lung Cancer (NSCLC) in Radiological Progression During Treatment With Nivolumab. *Cancers (Basel)* (2021) 13(13):3117. doi: 10.3390/cancers13133117

32. Rebuzzi SE, Signori A, Banna GL, Maruzzo M, De Giorgi U, Pedrazzoli P, et al. Inflammatory Indices and Clinical Factors in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab: The Development of a Novel Prognostic Score (Meet-URO 15 Study). *Ther Adv Med Oncol* (2021) 13:17588359211019642. doi: 10.1177/17588359211019642

33. Kanda M, Kodera Y. Molecular Mechanisms of Peritoneal Dissemination in Cancers (Basel) (2018) 5(2):e000670. doi: 10.1136/esmoopen-2020-000670

34. Min KW, Kwon MJ, Kim DH, Son BK, Kim EK, Oh YH, et al. Persistent Elevation of Postoperative Neutrophil-to-Lymphocyte Ratio: A Better Predictor of Survival in Gastric Cancer Than Elevated Preoperative Neutrophil-to-Lymphocyte Ratio. *Sci Rep* (2017) 7:13967. doi: 10.1038/s41598-017-13969-x

35. Ruan D, Chen Y, Wei X, Wang Y, Wang Z, Wu H, et al. Elevated Peripheral Blood Neutrophil-to-Lymphocyte Ratio Is Associated With an Immunosuppressive Tumour Microenvironment and Decreased Benefit of PD-1 Antibody in Advanced Gastric Cancer. *Gastroenterol Rep* (2021) 5:9 (6):560–70. doi: 10.1093/gastro/goa0532

36. Wei XL, Xu JY, Wang DS, Chen DL, Ren C, Li JN, et al. Baseline Lesion Number as an Efficacy Predictive and Independent Prognostic Factor and Its Joint Utility With TMB for PD-1 Inhibitor Treatment in Advanced Gastric Cancer. *Ther Adv Med Oncol* (2021) 13:1758835921198896. doi: 10.1177/1758835921198896

37. Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, et al. Prognostic Factors in Patients Treated With Second-Line Chemotherapy for Advanced Gastric Cancer: Results From the Randomized Prospective Phase III FFCD-0307 Trial. *Gastric Cancer* (2019) 22(3):577–86. doi: 10.1007/s10120-018-0885-z

38. Kim J, Hong J, Kim S, Park S, Jekal S, Choi J, et al. Clinical Scoring System for the Prediction of Survival of Patients With Advanced Gastric Cancer. *ESMO Open* (2020) 5(2):e000670. doi: 10.1136/esmoopen-2020-000670

39. Kartolo A, Holstead R, Khalid S, Emack J, Hopman W, Robinson A, et al. Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy. *Immunotherapy* (2020) 12:785–98. doi: 10.2217/int-2020-0105

40. Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of Tumor Cells by Natural Killer Cells in Mouse Is Impeded by Platelets. *Cancer Res* (1999) 59:1295–300.

41. Xu XR, Carrim N, Neves MA, McKeown T, Stratton TW, Coelho RM, et al. Platelets and Platelet Adhesion Molecules: Novel Mechanisms of Thrombosis and Anti-Thrombotic Therapies. *Thromb J* (2016) 14:29. doi: 10.1186/s12995-016-0100-6

42. Leblanc R, Peyruchaud O. Metastasis: New Functional Implications of Platelets and Megakaryocytes. *Blood* (2016) 128:24–31. doi: 10.1182/blood-2016-01-63639

43. Takamoto A, Okitaka M, Takagi S, Takami M, Sato S, Nishio M, et al. A Critical Role of Platelet TGF-ß Release in Podoplanin-Mediated Tumour Invasion and Metastasis. *Sci Rep* (2017) 7:42186. doi: 10.1038/srep42186

44. Haemmerle M, Stone RL, Menter DG, Afshar-Kharghan V, Sood AK. The Platelet Lifeline to Cancer: Challenges and Opportunities. *Cancer Cell* (2018) 33:965–83. doi: 10.1016/j.ccell.2018.03.002

45. Gay LJ, Felding-Habermann B. Contribution of Platelets to Tumour Metastasis. *Nat Rev Cancer* (2011) 11:123–34. doi: 10.1038/nrc3004

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

*Copyright © 2022 Qu, Wang, Wang, Jiao, Li, Wei, Zhao, Zhang, Zhang and Gu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*